Modulation of circulating levels of advanced glycation end products and its impact on intima-media thickness of both common carotid arteries: CORDIOPREV randomised controlled trial.
Humans
Glycation End Products, Advanced
/ blood
Male
Carotid Intima-Media Thickness
Diet, Mediterranean
Female
Middle Aged
Aged
Receptor for Advanced Glycation End Products
/ blood
Biomarkers
/ blood
Carotid Artery, Common
/ diagnostic imaging
Treatment Outcome
Diet, Fat-Restricted
Carotid Artery Diseases
/ blood
Time Factors
Disease Progression
Antigens, Neoplasm
Lactoylglutathione Lyase
Mitogen-Activated Protein Kinases
Advanced glycation end products
Atherosclerosis
Dietary intervention
Mediterranean diet
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
21
07
2024
accepted:
21
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
14
10
2024
Statut:
epublish
Résumé
Increasing evidence supports the role of advanced glycation end products (AGEs) in atherosclerosis in both diabetic and non-diabetic patients, suggesting that therapeutic strategies targeting AGEs may offer potential benefits in this population. The Mediterranean diet is associated with improved biomarkers and anthropometric measurements related with atherosclerosis in addition to its ability to modulate AGE metabolism. Our aim was to determine whether the reduction in atherosclerosis progression (measured by changes in intima-media thickness of both common carotid arteries (IMT-CC)), observed after consumption of a Mediterranean diet compared to a low-fat diet, is associated with a modulation of circulating AGE levels in patients with coronary heart disease (CHD). 1002 CHD patients were divided in: (1) Non-increased IMT-CC patients, whose IMT-CC was reduced or not changed after dietary intervention and (2) Increased IMT-CC patients, whose IMT-CC was increased after dietary intervention. Serum AGE levels (methylglyoxal-MG and Nε-Carboxymethyllysine-CML) and parameters related to AGE metabolism (AGER1 and GloxI mRNA and sRAGE levels) and reduced glutathione (GSH) levels were measured before and after 5-years of dietary intervention. The Mediterranean diet did not affect MG levels, whereas the low-fat diet significantly increased them compared to baseline (p = 0.029), leading to lower MG levels following the Mediterranean diet than the low-fat diet (p < 0.001). The Mediterranean diet, but not the low-fat diet, produced an upregulation of AGE metabolism, with increased AGER1 and GloxI gene expression as well as increased GSH and sRAGE levels in Non-increased IMT-CC patients (all p < 0.05). Although the Mediterranean diet increased MG levels in Increased IMT-CC patients, this increment was lower compared to the low-fat diet (all p < 0.05). Our results suggest that an improvement in modulation of AGE metabolism, which facilitates better management of circulating AGE levels, may be one of the mechanisms through which the Mediterranean diet, compared to a low-fat diet, reduces the progression of atherosclerosis in patients with CHD. Trial registration https://clinicaltrials.gov/ct2/show/NCT00924937 , Clinicaltrials.gov number, NCT00924937.
Sections du résumé
BACKGROUND
BACKGROUND
Increasing evidence supports the role of advanced glycation end products (AGEs) in atherosclerosis in both diabetic and non-diabetic patients, suggesting that therapeutic strategies targeting AGEs may offer potential benefits in this population. The Mediterranean diet is associated with improved biomarkers and anthropometric measurements related with atherosclerosis in addition to its ability to modulate AGE metabolism. Our aim was to determine whether the reduction in atherosclerosis progression (measured by changes in intima-media thickness of both common carotid arteries (IMT-CC)), observed after consumption of a Mediterranean diet compared to a low-fat diet, is associated with a modulation of circulating AGE levels in patients with coronary heart disease (CHD).
METHODS
METHODS
1002 CHD patients were divided in: (1) Non-increased IMT-CC patients, whose IMT-CC was reduced or not changed after dietary intervention and (2) Increased IMT-CC patients, whose IMT-CC was increased after dietary intervention. Serum AGE levels (methylglyoxal-MG and Nε-Carboxymethyllysine-CML) and parameters related to AGE metabolism (AGER1 and GloxI mRNA and sRAGE levels) and reduced glutathione (GSH) levels were measured before and after 5-years of dietary intervention.
RESULTS
RESULTS
The Mediterranean diet did not affect MG levels, whereas the low-fat diet significantly increased them compared to baseline (p = 0.029), leading to lower MG levels following the Mediterranean diet than the low-fat diet (p < 0.001). The Mediterranean diet, but not the low-fat diet, produced an upregulation of AGE metabolism, with increased AGER1 and GloxI gene expression as well as increased GSH and sRAGE levels in Non-increased IMT-CC patients (all p < 0.05). Although the Mediterranean diet increased MG levels in Increased IMT-CC patients, this increment was lower compared to the low-fat diet (all p < 0.05).
CONCLUSIONS
CONCLUSIONS
Our results suggest that an improvement in modulation of AGE metabolism, which facilitates better management of circulating AGE levels, may be one of the mechanisms through which the Mediterranean diet, compared to a low-fat diet, reduces the progression of atherosclerosis in patients with CHD. Trial registration https://clinicaltrials.gov/ct2/show/NCT00924937 , Clinicaltrials.gov number, NCT00924937.
Identifiants
pubmed: 39402581
doi: 10.1186/s12933-024-02451-4
pii: 10.1186/s12933-024-02451-4
doi:
Substances chimiques
Glycation End Products, Advanced
0
Receptor for Advanced Glycation End Products
0
Biomarkers
0
AGER protein, human
0
sRAGE protein, human
0
GLO1 protein, human
EC 4.4.1.5
MOK protein, human
EC 2.7.11.22
Antigens, Neoplasm
0
Lactoylglutathione Lyase
EC 4.4.1.5
Mitogen-Activated Protein Kinases
EC 2.7.11.24
Banques de données
ClinicalTrials.gov
['NCT00924937']
Types de publication
Journal Article
Randomized Controlled Trial
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
361Subventions
Organisme : Instituto de Salud Carlos III
ID : PI18/01822
Organisme : Consejería de Salud y Familias, Junta de Andalucía
ID : PC-0283-2017
Organisme : Ministerio de Ciencia e Innovación
ID : AGL2012-39615
Organisme : Fundación Patrimonio Comunal Olivarero
ID : Cordioprev-CEAS, 1/2016
Informations de copyright
© 2024. The Author(s).
Références
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global Burden of Cardiovascular diseases and Risk factors, 1990–2019: Update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021.
pubmed: 33309175
pmcid: 7755038
doi: 10.1016/j.jacc.2020.11.010
Hess CN, Clare RM, Neely ML, Tricoci P, Mahaffey KW, James SK, Alexander JH, Held C, Lopes RD, Fox KAA, et al. Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. Am Heart J. 2017;187:194–203.
pubmed: 28454804
doi: 10.1016/j.ahj.2017.01.016
Piepoli MF, Corra U, Dendale P, Frederix I, Prescott E, Schmid JP, Cupples M, Deaton C, Doherty P, Giannuzzi P, et al. Challenges in secondary prevention after acute myocardial infarction: a call for action. Eur Heart J Acute Cardiovasc Care. 2017;6(4):299–310.
pubmed: 28608759
doi: 10.1177/2048872616689773
Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290(7):891–7.
pubmed: 12928465
doi: 10.1001/jama.290.7.891
Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, et al. Heart Disease and Stroke Statistics-2016 update: a Report from the American Heart Association. Circulation. 2016;133(4):e38–360.
Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, Yong A, Striker GE, Vlassara H. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911–e916912.
pubmed: 20497781
pmcid: 3704564
doi: 10.1016/j.jada.2010.03.018
Maasen K, Eussen S, Scheijen J, van der Kallen CJH, Dagnelie PC, Opperhuizen A, Stehouwer CDA, van Greevenbroek MMJ, Schalkwijk CG. Higher habitual intake of dietary dicarbonyls is associated with higher corresponding plasma dicarbonyl concentrations and skin autofluorescence: the Maastricht Study. Am J Clin Nutr. 2022;115(1):34–44.
pubmed: 34625788
doi: 10.1093/ajcn/nqab329
Scheijen J, Hanssen NMJ, van Greevenbroek MM, Van der Kallen CJ, Feskens EJM, Stehouwer CDA, Schalkwijk CG. Dietary intake of advanced glycation endproducts is associated with higher levels of advanced glycation endproducts in plasma and urine: the CODAM study. Clin Nutr. 2018;37(3):919–25.
pubmed: 29381139
doi: 10.1016/j.clnu.2017.03.019
Hanssen NM, Beulens JW, van Dieren S, Scheijen JL, van der Spijkerman AD, van der Schouw AM, Stehouwer YT, Schalkwijk CD. Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL). Diabetes. 2015;64(1):257–65.
pubmed: 24848072
doi: 10.2337/db13-1864
Hirai T, Fujiyoshi K, Yamada S, Matsumoto T, Kikuchi J, Ishida K, Ishida M, Shigeta K, Tojo T. Association between fingertip-measured advanced glycation end products and cardiovascular events in outpatients with cardiovascular disease. Cardiovasc Diabetol. 2023;22(1):213.
pubmed: 37592261
pmcid: 10436644
doi: 10.1186/s12933-023-01953-x
Yubero-Serrano EM, Perez-Martinez P. Advanced Glycation End products and their involvement in Cardiovascular Disease. Angiology. 2020;71(8):698–700.
pubmed: 32242451
doi: 10.1177/0003319720916301
Singh S, Siva BV, Ravichandiran V. Advanced Glycation End products: key player of the pathogenesis of atherosclerosis. Glycoconj J. 2022;39(4):547–63.
pubmed: 35579827
doi: 10.1007/s10719-022-10063-x
Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Volzke H, Tuomainen TP, Sander D, Plichart M, Catapano AL, Robertson CM, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet. 2012;379(9831):2053–62.
pubmed: 22541275
pmcid: 3918517
doi: 10.1016/S0140-6736(12)60441-3
Ying L, Shen Y, Zhang Y, Wang Y, Liu Y, Yin J, Wang Y, Yin J, Zhu W, Bao Y, et al. Advanced glycation end products via skin autofluorescence as potential marker of carotid atherosclerosis in patients with type 2 diabetes. Volume 31. Nutrition, metabolism, and cardiovascular diseases: NMCD; 2021. pp. 3449–56. 12.
Chen J, Arshi B, Waqas K, Lu T, Bos D, Ikram MA, Uitterlinden AG, Kavousi M, Zillikens MC. Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study. Cardiovasc Diabetol. 2023;22(1):326.
pubmed: 38017418
pmcid: 10685533
doi: 10.1186/s12933-023-02052-7
Pan J, Bao X, Goncalves I, Jujic A, Engstrom G. Skin autofluorescence, a measure of tissue accumulation of advanced glycation end products, is associated with subclinical atherosclerosis in coronary and carotid arteries. Atherosclerosis. 2022;345:26–32.
pubmed: 35196628
doi: 10.1016/j.atherosclerosis.2022.02.014
Fishman SL, Sonmez H, Basman C, Singh V, Poretsky L. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med. 2018;24(1):59.
pubmed: 30470170
pmcid: 6251169
doi: 10.1186/s10020-018-0060-3
de la Cruz-Ares S, Cardelo MP, Gutierrez-Mariscal FM, Torres-Pena JD, Garcia-Rios A, Katsiki N, Malagon MM, Lopez-Miranda J, Perez-Martinez P, Yubero-Serrano EM. Endothelial dysfunction and Advanced Glycation End products in patients with newly diagnosed Versus established diabetes: from the CORDIOPREV Study. Nutrients 2020, 12(1).
Reddy VP. Oxidative stress in health and disease. Biomedicines 2023, 11(11).
Saremi A, Howell S, Schwenke DC, Bahn G, Beisswenger PJ, Reaven PD, Investigators V. Advanced Glycation End products, Oxidation products, and the extent of atherosclerosis during the VA Diabetes Trial and follow-up study. Diabetes Care. 2017;40(4):591–8.
pubmed: 28148544
pmcid: 5360279
doi: 10.2337/dc16-1875
Prasad C, Davis KE, Imrhan V, Juma S, Vijayagopal P. Advanced Glycation End products and risks for Chronic diseases: intervening through Lifestyle Modification. Am J Lifestyle Med. 2019;13(4):384–404.
pubmed: 31285723
doi: 10.1177/1559827617708991
Gutierrez-Mariscal FM, Cardelo MP, de la Cruz S, Alcala-Diaz JF, Roncero-Ramos I, Guler I, Vals-Delgado C, Lopez-Moreno A, Luque RM, Delgado-Lista J, et al. Reduction in circulating Advanced Glycation End products by Mediterranean Diet is Associated with increased likelihood of type 2 diabetes remission in patients with Coronary Heart Disease: from the Cordioprev Study. Mol Nutr Food Res. 2021;65(1):e1901290.
pubmed: 32529753
doi: 10.1002/mnfr.201901290
Lopez-Moreno J, Quintana-Navarro GM, Camargo A, Jimenez-Lucena R, Delgado-Lista J, Marin C, Tinahones FJ, Striker GE, Roche HM, Perez-Martinez P et al. Dietary fat quantity and quality modifies advanced glycation end products metabolism in patients with metabolic syndrome. Mol Nutr Food Res. 2017;61(8).
Lopez-Moreno J, Quintana-Navarro GM, Delgado-Lista J, Garcia-Rios A, Delgado-Casado N, Camargo A, Perez-Martinez P, Striker GE, Tinahones FJ, Perez-Jimenez F, et al. Mediterranean Diet reduces serum advanced glycation end products and increases antioxidant defenses in Elderly adults: a Randomized Controlled Trial. J Am Geriatr Soc. 2016;64(4):901–4.
pubmed: 27100598
doi: 10.1111/jgs.14062
Jimenez-Torres J, Alcala-Diaz JF, Torres-Pena JD, Gutierrez-Mariscal FM, Leon-Acuna A, Gomez-Luna P, Fernandez-Gandara C, Quintana-Navarro GM, Fernandez-Garcia JC, Perez-Martinez P, et al. Mediterranean diet reduces atherosclerosis progression in coronary heart disease: an analysis of the CORDIOPREV randomized controlled trial. Stroke. 2021;52(11):3440–9.
pubmed: 34372670
doi: 10.1161/STROKEAHA.120.033214
Delgado-Lista J, Alcala-Diaz JF, Torres-Pena JD, Quintana-Navarro GM, Fuentes F, Garcia-Rios A, Ortiz-Morales AM, Gonzalez-Requero AI, Perez-Caballero AI, Yubero-Serrano EM, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022;399(10338):1876–85.
pubmed: 35525255
doi: 10.1016/S0140-6736(22)00122-2
Delgado-Lista J, Perez-Martinez P, Garcia-Rios A, Alcala-Diaz JF, Perez-Caballero AI, Gomez-Delgado F, Fuentes F, Quintana-Navarro G, Lopez-Segura F, Ortiz-Morales AM, et al. CORonary Diet intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV study): rationale, methods, and baseline characteristics: a clinical trial comparing the efficacy of a Mediterranean diet rich in olive oil versus a low-fat diet on cardiovascular disease in coronary patients. Am Heart J. 2016;177:42–50.
pubmed: 27297848
pmcid: 4910622
doi: 10.1016/j.ahj.2016.04.011
Quintana-Navarro GM, Alcala-Diaz JF, Lopez-Moreno J, Perez-Corral I, Leon-Acuna A, Torres-Pena JD, Rangel-Zuniga OA, Arenas de Larriva AP, Corina A, Camargo A, et al. Long-term dietary adherence and changes in dietary intake in coronary patients after intervention with a Mediterranean diet or a low-fat diet: the CORDIOPREV randomized trial. Eur J Nutr. 2020;59(5):2099–110.
pubmed: 31342228
doi: 10.1007/s00394-019-02059-5
Yubero-Serrano EM, Fernandez-Gandara C, Garcia-Rios A, Rangel-Zuñiga OA, Gutierrez-Mariscal FM, Torres-Peña JD, Marin C, Lopez-Moreno J, Castaño JP, Delgado-Lista J, et al. Mediterranean diet and endothelial function in patients with coronary heart disease: an analysis of the CORDIOPREV randomized controlled trial. PLoS Med. 2020;17(9):e1003282.
pubmed: 32903262
pmcid: 7480872
doi: 10.1371/journal.pmed.1003282
Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS, American Society of Echocardiography Carotid Intima-Media Thickness Task F. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93–111. quiz 189–190.
pubmed: 18261694
doi: 10.1016/j.echo.2007.11.011
Arsov S, Graaff R, van Oeveren W, Stegmayr B, Sikole A, Rakhorst G, Smit AJ. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. Clin Chem Lab Med. 2014;52(1):11–20.
pubmed: 23612551
doi: 10.1515/cclm-2012-0832
Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med. 2002;8(7):337–46.
pubmed: 12393931
pmcid: 2040002
doi: 10.1007/BF03402014
Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A. 2012;109(39):15888–93.
pubmed: 22908267
pmcid: 3465382
doi: 10.1073/pnas.1205847109
Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99(24):15596–601.
pubmed: 12429856
pmcid: 137762
doi: 10.1073/pnas.242407999
Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011;7(9):526–39.
pubmed: 21610689
pmcid: 3708644
doi: 10.1038/nrendo.2011.74
Cruz-Teno C, Perez-Martinez P, Delgado-Lista J, Yubero-Serrano EM, Garcia-Rios A, Marin C, Gomez P, Jimenez-Gomez Y, Camargo A, Rodriguez-Cantalejo F, et al. Dietary fat modifies the postprandial inflammatory state in subjects with metabolic syndrome: the LIPGENE study. Mol Nutr Food Res. 2012;56(6):854–65.
pubmed: 22707261
doi: 10.1002/mnfr.201200096
Peng Y, Liu F, Qiao Y, Wang P, Du H, Si C, Wang X, Chen K, Song F. Genetically modified circulating levels of Advanced Glycation End-products and their soluble receptor (AGEs-RAGE Axis) with risk and mortality of breast Cancer. Cancers 2022, 14(24).
Ortiz-Morales AM, Alcala-Diaz JF, Rangel-Zuñiga OA, Corina A, Quintana-Navarro G, Cardelo MP, Yubero-Serrano E, Malagon MM, Delgado-Lista J, Ordovas JM, et al. Biological senescence risk score. A practical tool to predict biological senescence status. Eur J Clin Invest. 2020;50(11):e13305.
pubmed: 32506428
doi: 10.1111/eci.13305
Won KB, Chang HJ, Park SH, Hong SY, Jang Y, Chung N. High serum advanced glycation end-products predict coronary artery disease irrespective of arterial stiffness in diabetic patients. Korean Circ J. 2012;42(5):335–40.
pubmed: 22701499
pmcid: 3369965
doi: 10.4070/kcj.2012.42.5.335
van Eupen MG, Schram MT, Colhoun HM, Scheijen JL, Stehouwer CD, Schalkwijk CG. Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification. Cardiovasc Diabetol. 2013;12:149.
pubmed: 24134530
pmcid: 4015708
doi: 10.1186/1475-2840-12-149
Kizer JR, Benkeser D, Arnold AM, Ix JH, Mukamal KJ, Djousse L, Tracy RP, Siscovick DS, Psaty BM, Zieman SJ. Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults. Atherosclerosis. 2014;235(1):116–21.
pubmed: 24825341
pmcid: 4169874
doi: 10.1016/j.atherosclerosis.2014.04.013
Ogawa S, Nakayama K, Nakayama M, Mori T, Matsushima M, Okamura M, Senda M, Nako K, Miyata T, Ito S. Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. Hypertension. 2010;56(3):471–6.
pubmed: 20644005
doi: 10.1161/HYPERTENSIONAHA.110.156786
Hanssen NMJ, Westerink J, Scheijen J, van der Graaf Y, Stehouwer CDA, Schalkwijk CG, Group SS. Higher plasma methylglyoxal levels are Associated With Incident Cardiovascular Disease and Mortality in individuals with type 2 diabetes. Diabetes Care. 2018;41(8):1689–95.
pubmed: 29784769
doi: 10.2337/dc18-0159
Saremi A, Howell S, Schwenke DC, Bahn G, Beisswenger PJ, Reaven PD. Advanced Glycation End products, Oxidation products, and the extent of atherosclerosis during the VA Diabetes Trial and follow-up study. Diabetes Care. 2017;40(4):591–8.
pubmed: 28148544
pmcid: 5360279
doi: 10.2337/dc16-1875
Lu J, Ji J, Meng H, Wang D, Jiang B, Liu L, Randell E, Adeli K, Meng QH. The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats. Cardiovasc Diabetol. 2013;12:58.
pubmed: 23561047
pmcid: 3642024
doi: 10.1186/1475-2840-12-58
Monnier VM, Sun W, Gao X, Sell DR, Cleary PA, Lachin JM, Genuth S, Group DER. Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Cardiovasc Diabetol. 2015;14:118.
pubmed: 26341632
pmcid: 4560872
doi: 10.1186/s12933-015-0266-4
Hadas K, Randriamboavonjy V, Elgheznawy A, Mann A, Fleming I. Methylglyoxal induces platelet hyperaggregation and reduces thrombus stability by activating PKC and inhibiting PI3K/Akt pathway. PLoS ONE. 2013;8(9):e74401.
pubmed: 24058557
pmcid: 3772821
doi: 10.1371/journal.pone.0074401
Nakamura T, Tsujimoto T, Yasuda K, Ueki K, Kajio H. Continuous low serum levels of advanced glycation end products and low risk of cardiovascular disease in patients with poorly controlled type 2 diabetes. Cardiovasc Diabetol. 2023;22(1):147.
pubmed: 37353776
pmcid: 10290294
doi: 10.1186/s12933-023-01882-9
Grosjean F, Yubero-Serrano EM, Zheng F, Esposito V, Swamy S, Elliot SJ, Cai W, Vlassara H, Salem F, Striker GE. Pharmacologic control of oxidative stress and inflammation determines whether diabetic glomerulosclerosis progresses or decreases: a pilot study in sclerosis-prone mice. PLoS ONE. 2018;13(9):e0204366.
pubmed: 30252878
pmcid: 6155507
doi: 10.1371/journal.pone.0204366
Yue K, Mao B, Tang X, Zhang Q, Zhao J, Cui S, Chen W. Recent updates in anti-glycation strategies: selection of natural products and lactic acid bacteria as potential inhibitors based on the multi-pathway anti-glycation targets. Crit Rev Food Sci Nutr 2023:1–18.
Zawada A, Machowiak A, Rychter AM, Ratajczak AE, Szymczak-Tomczak A, Dobrowolska A, Krela-Kaźmierczak I. Accumulation of Advanced Glycation End-products in the body and Dietary habits. Nutrients. 2022;14(19):3982.
pubmed: 36235635
pmcid: 9572209
doi: 10.3390/nu14193982
Grosso G, Marventano S, Yang J, Micek A, Pajak A, Scalfi L, Galvano F, Kales SN. A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: are individual components equal? Crit Rev Food Sci Nutr. 2017;57(15):3218–32.
pubmed: 26528631
doi: 10.1080/10408398.2015.1107021
Martinez-Gonzalez MA, Gea A, Ruiz-Canela M. The Mediterranean Diet and Cardiovascular Health. Circ Res. 2019;124(5):779–98.
pubmed: 30817261
doi: 10.1161/CIRCRESAHA.118.313348
Podadera-Herreros A, Alcala-Diaz JF, Gutierrez-Mariscal FM, Jimenez-Torres J, Cruz-Ares S, Arenas-de Larriva AP, Cardelo MP, Torres-Pena JD, Luque RM, Ordovas JM, et al. Long-term consumption of a mediterranean diet or a low-fat diet on kidney function in coronary heart disease patients: the CORDIOPREV randomized controlled trial. Clin Nutr. 2022;41(2):552–9.
pubmed: 35030530
doi: 10.1016/j.clnu.2021.12.041
Camargo A, Rangel-Zuniga OA, Haro C, Meza-Miranda ER, Pena-Orihuela P, Meneses ME, Marin C, Yubero-Serrano EM, Perez-Martinez P, Delgado-Lista J, et al. Olive oil phenolic compounds decrease the postprandial inflammatory response by reducing postprandial plasma lipopolysaccharide levels. Food Chem. 2014;162:161–71.
pubmed: 24874372
doi: 10.1016/j.foodchem.2014.04.047
Shi B, Guo X, Liu H, Jiang K, Liu L, Yan N, Farag MA, Liu L. Dissecting Maillard reaction production in fried foods: formation mechanisms, sensory characteristic attribution, control strategy, and gut homeostasis regulation. Food Chem. 2024;438:137994.
pubmed: 37984001
doi: 10.1016/j.foodchem.2023.137994
Hanssen NM, Stehouwer CD, Schalkwijk CG. Methylglyoxal and glyoxalase I in atherosclerosis. Biochem Soc Trans. 2014;42(2):443–9.
pubmed: 24646258
doi: 10.1042/BST20140001
Cai W, He JC, Zhu L, Lu C, Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci U S A. 2006;103(37):13801–6.
pubmed: 16954185
pmcid: 1564251
doi: 10.1073/pnas.0600362103
Delrue C, Delanghe JR, Speeckaert MM. The role of sRAGE in cardiovascular diseases. Adv Clin Chem. 2023;117:53–102.
pubmed: 37973322
doi: 10.1016/bs.acc.2023.08.005
Grauen Larsen H, Marinkovic G, Nilsson PM, Nilsson J, Engstrom G, Melander O, Orho-Melander M, Schiopu A. High plasma sRAGE (soluble receptor for Advanced Glycation End products) is Associated with slower carotid intima-media thickness progression and lower risk for First-Time coronary events and mortality. Arterioscler Thromb Vasc Biol. 2019;39(5):925–33.
pubmed: 30917679
doi: 10.1161/ATVBAHA.118.312319
Heier M, Margeirsdottir HD, Gaarder M, Stensaeth KH, Brunborg C, Torjesen PA, Seljeflot I, Hanssen KF, Dahl-Jorgensen K. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study. Cardiovasc Diabetol. 2015;14:126.
pubmed: 26408307
pmcid: 4582642
doi: 10.1186/s12933-015-0292-2
Corica D, Pepe G, Curro M, Aversa T, Tropeano A, Ientile R, Wasniewska M. Methods to investigate advanced glycation end-product and their application in clinical practice. Methods. 2022;203:90–102.
pubmed: 34942356
doi: 10.1016/j.ymeth.2021.12.008
Li L, Zhuang Y, Zou X, Chen M, Cui B, Jiao Y, Cheng Y. Advanced Glycation End products: a comprehensive review of their detection and occurrence in Food. Foods 2023, 12(11).